Key Takeaway: PMV Pharmaceuticals has successfully completed patient enrollment for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial focused on platinum-resistant/refractory ovarian cancer. The company plans to submit a New Drug Application (NDA) for Rezatapopt in the first quarter of 2027, indicating progress in their clinical development pipeline.
Market Sentiment Analysis
POSITIVE FACTORS
Enrollment for the Phase 2 clinical trial has been completed.
NDA submission for Rezatapopt is planned for early 2027.
Focus on platinum-resistant/refractory ovarian cancer shows commitment to targeted therapy.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+76%
120-day peak, hindsight
Typical move
22.7%
average across 4 past catalysts
Cash runway
~12 mo
Medium dilution risk
Lead asset
rezatapopt
Phase 1 · Advanced Solid Tumor
Full Press Release Details
Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027 Cash, cash
Frequently Asked Questions
What trial did PMV Pharmaceuticals complete enrollment for?
PMV Pharmaceuticals completed enrollment for the Phase 2 monotherapy portion of the PYNNACLE trial.
What is the focus of the PYNNACLE clinical trial?
The PYNNACLE clinical trial focuses on platinum-resistant/refractory ovarian cancer.
When is the NDA submission for Rezatapopt planned?
The NDA submission for Rezatapopt is planned for the first quarter of 2027.